Cardiometabolic risk factors among HIV patients on antiretroviral therapy
Authors:
- James N KiageJKJames N Kiage
- Douglas C HeimburgerDHDouglas C Heimburger
- Christopher K NyirendaCNChristopher K Nyirenda
- Melissa F WellonsMWMelissa F Wellons
- Shashwatee BagchiSBShashwatee Bagchi
- Benjamin H ChiBCBenjamin H Chi
- John R KoetheJKJohn R Koethe
- Donna K ArnettDADonna K Arnett
- Edmond K KabagambeEKEdmond K Kabagambe
Open Access
- 10 April 2013
- journal article
- research article
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 12 (1) , 50
Abstract
Background: HIV and combination antiretroviral therapy (cART) may increase cardiovascular disease (CVD) risk. We assessed the early effects of cART on CVD risk markers in a population with presumed low CVD risk. Methods: Adult patients (n=118) in Lusaka, Zambia were recruited at the time of initiation of cART for HIV/AIDS. Cardiometabolic risk factors were measured before and 90 days after starting cART. Participants were grouped according to cART regimens: Zidovudine + Lamivudine + Nevirapine (n=58); Stavudine + Lamivudine + Nevirapine (n=43); and ‘other’ (Zidovudine + Lamivudine + Efavirenz, Stavudine + Lamivudine + Efavirenz, Tenofovir + Emtricitabine + Efavirenz or Tenofovir + Emtricitabine + Nevirapine, n=17). ANOVA was used to test whether changes in cardiometabolic risk markers varied by cART regimen. Results: From baseline to 90 days after initiation of cART, the prevalence of low levels of high-density lipoprotein cholesterol (PP=0.03) and the homeostasis model assessment of insulin resistance ≥3.0 (1.7% vs. 17.0%, PP<0.001). These changes in cardiometabolic risk markers were independent of the cART regimen. Conclusion: Our results suggest that short-term cART is associated with a cardioprotective lipid profile in Zambia and a tendency towards insulin resistance regardless of the cART regimen.Keywords
This publication has 42 references indexed in Scilit:
- First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional studyAIDS Research and Therapy, 2011
- Inflammation Biomarkers and Risk of All-Cause Mortality in the Reasons for Geographic and Racial Differences in Stroke CohortAmerican Journal of Epidemiology, 2011
- Dyslipidemia in an HIV-Positive Antiretroviral Treatment-Naive Population in Dar es Salaam, TanzaniaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Serum Phosphate Predicts Early Mortality in Adults Starting Antiretroviral Therapy in Lusaka, Zambia: A Prospective Cohort StudyPLOS ONE, 2010
- Early Clinical and Programmatic Outcomes with Tenofovir-Based Antiretroviral Therapy in ZambiaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Lipoprotein particle subclasses, cardiovascular disease and HIV infectionAtherosclerosis, 2009
- Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaborationThe Lancet, 2008
- Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2007
- Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adultsAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1PLOS Medicine, 2004